Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Bison Capital Acquisition Corp. Announces Pricing of $52.5 Million Initial Public Offering
-
Constellation Alpha Capital Corp. Announces Pricing of $125 Million Initial Public Offering
-
AveXis (AVXS) Plans $200M Common Stock Offering
-
AveXis Announces Proposed Public Offering of Common Stock
-
Chardan Capital Markets Upgrades Clovis Oncology (CLVS) to Neutral
-
Regulus Therapeutics (RGLS): Cutting PT By 50% - Chardan
-
Kiadis Pharma Raises €5 Million in Private Placement with Institutional Investors
-
Chardan Capital Markets Starts Catalyst Biosciences (CBIO) at Buy
-
Microbot Medical (MBOT) Announces Closing of 3.75M Registered Direct Common Offering
-
Microbot Medical Announces Closing of $10 Million Registered Direct Offering of Common Stock
-
KBL Merger Corp. IV Completes $100 Million Initial Public Offering
-
HealthEquity, Inc (HQY) PT Raised to $57 at Chardan Capital Markets; 'Strong Execution'
-
Chardan Capital Markets Starts Castlight Health Inc. (CSLT) at Buy
-
Comhear, Inc. Closes $12M Series A Financing; Expands Executive Management Team and Board of Directors
-
Microbot Medical (MBOT) Announces $10M Direct Offering of Common Stock
-
Microbot Medical Announces $10 Million Registered Direct Offering of Common Stock
-
Pre-Open Movers 06/02: (LULU) (SGYP) (AVGO) Higher; (RH) (BOOT) (SVRA) Lower (more...)
-
Chardan Capital Markets Starts Biocept (BIOC) at Buy, "Pure Play Liquid Biopsy Story"
-
KBL Merger Corp. IV Announces Pricing of $100 Million Initial Public Offering
-
Amicus Therapeutics (FOLD): Priority Review Voucher Is A $125 Million Call Option - Chardan
-
Chardan Capital Markets Upgrades Akari Therapeutics (AKTX) to Neutral
-
Chardan Capital Markets Starts Assembly Biosciences (ASMB) at Buy, "Sensitivity analyses suggest considerable upside"
-
Spring Bank Pharmaceuticals (SBPH) PT More than Doubled to $34 at Chardan Capital Markets
-
Castlight Health to Participate in Upcoming Investor Conferences
-
Chardan Capital Markets Starts Model N, Inc. (MODN) at Buy; Undervalued Versus Peers
-
Smith Micro (SMSI) Announces $2.2M Registered Direct Offering of Common Stock
-
Smith Micro Announces $2.2 Million Registered Direct Offering of Common Stock
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $110 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades CaesarStone Sdot-Yam (CSTE) to Neutral on Valuation
-
Astrotech (ASTC) Subsidiary to Pursue Strategic Alternatives
-
Astrotech Subsidiary 1st Detect to Pursue Strategic Alternatives
-
Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets
-
Lion Biotechnologies (LBIO) PT Raised to $20 at Chardan Capital Markets, "Leader In Precision Immuno-Oncology"
-
Chardan Capital Markets Starts Spring Bank Pharmaceuticals (SBPH) at Buy; Can Lead in HBV
-
Forum Merger Corporation Class A Common Stock, Warrants and Rights to Commence Trading Separately on May 2, 2017
-
REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
-
Chardan Capital Markets Reiterates Sell Rating and $6.50 PT on Akari Therapeutcis (AKTX); 'Weak Efficacy for Coversin in the Ph2 PNH COBALT Trial'
-
SRAX Announces Offering of $3.72 Million of Secured Convertible Debentures
-
Akari Therapeutics (AKTX) PT Raised to $6.50 at Chardan Capital Markets; 'Skepticism on Coversin in PNH'
-
Forum Merger Corporation Completes $150,000,000 Initial Public Offering
-
PlacementTracker Publishes Q1 2017 Private Placement Market League Tables
-
Lion Biotechnologies (LBIO): Reiterating Buy - Chardan
-
Regenxbio Inc. (RGNX) PT Raised to $50 at Chardan Capital Markets on News Dr. Olivier Danos is New CSO; 'Watershed Moment'
-
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
-
Forum Merger Corporation Announces Pricing of $150 Million Initial Public Offering
-
Ohr Pharmaceutical (OHRP) Prices $14.175M Offering of Common Stock and Warrants
-
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
-
Ohr Pharmaceutical (OHRP) Reports Proposed Equity Offering
-
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
-
Pre-Open Movers 04/04: (GNCMA) (PRTK) (CYCC) Higher; (AYI) (KATE) (NVDA) Lower (more...)

